Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Septerna, a clinical-stage biotech company focused on GPCR-targeted drug discovery, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jeffrey Finer, M.D., Ph.D., the company's CEO and co-founder, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. The presentation will be accessible via live webcast through Septerna's website and will remain available for 30 days afterward.

News Market Reaction – SEPN

-0.04%

-0.04% Session move

In the trading session that priced this news, SEPN declined 0.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43^rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

A live webcast will be available in the Investors & Media section of the company’s website at www.septerna.com and will be archived for 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

Media Contact:
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

FAQ

When is Septerna (SEPN) presenting at the 2025 J.P. Morgan Healthcare Conference?

Septerna is scheduled to present on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.

How can investors watch Septerna's J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via live webcast available in the Investors & Media section of Septerna's website (www.septerna.com). The recording will be archived for 30 days following the presentation.

Who will represent Septerna at the 2025 J.P. Morgan Healthcare Conference?

Jeffrey Finer, M.D., Ph.D., who serves as the chief executive officer and co-founder of Septerna, will represent the company at the conference.

What is Septerna's current business focus in the biotech industry?

Septerna is a clinical-stage biotechnology company that specializes in GPCR-targeted drug discovery, working to pioneer new developments in this field.